Rôle de la structure du génome viral sur la réplication du virus de l'hépatite C. Thèse Dr Univ Montr, 1866. ,
Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier, Rev Med Suisse, issue.7, pp.1683-1691, 2011. ,
Virus de l'hépatite C. 2015 *cited 2015 Feb 16+; Available from ,
Expérience de la Transplantation Hépatique chez les Patients Infectés par le VIH: Résultats à partir d'une Cohorte Monocentrique > 100 patients *Internet+, 2011. ,
Virus de l'hépatite C: Aspects virologiques *Internet+, 2014. ,
Expression and identification of hepatitis C virus polyprotein cleavage products, J Virol, vol.67, issue.3, pp.1385-95, 1993. ,
Assemblage in vitro de la nucléocapside du virus de l'hépatite C, 2006. ,
Replication of Hepatitis C Virus (HCV) ,
Quantitative Analysis of the Hepatitis C Virus Replication Complex, Journal of Virology, vol.79, issue.21, pp.13594-605, 2005. ,
DOI : 10.1128/JVI.79.21.13594-13605.2005
Hepatitis C virus genetic variability: pathogenic and clinical implications, Clinics in Liver Disease, vol.7, issue.1, pp.45-66, 2003. ,
DOI : 10.1016/S1089-3261(02)00065-X
The genetic diversity of hepatitis C virus and its implication for pathogenesis and resistance to treatment, Virologie, vol.9, issue.5, pp.343-55, 2005. ,
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource, Hepatology, vol.28, issue.244, pp.318-345, 2014. ,
DOI : 10.1002/hep.26744
La HAS définit la place des nouveaux traitements de l'hépatite C, 2014. ,
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors, Journal of Medical Virology, vol.15, issue.4, pp.546-55, 2010. ,
DOI : 10.1002/jmv.21734
Geographic prevalence of hepatitis C virus infection ,
Stratégies de dépistage biologique des hépatites virales B et C, 2011. ,
SIDA et transfusion sanguine ou l'affaire du sang contamin??. Les difficiles qualifications p??nales, M??decine et Maladies Infectieuses, vol.28, issue.1, pp.15-23, 1998. ,
DOI : 10.1016/S0399-077X(98)80032-2
Guide -Affection de longue durée -Hépatite Chronique C, 2006. ,
Nucleic Acid Testing (NAT) of Organ Donors: Is the ???Best??? Test the Right Test? A Consensus Conference Report, American Journal of Transplantation, vol.9, issue.RR-1, pp.889-99, 2010. ,
DOI : 10.1111/j.1600-6143.2009.02992.x
Ministère de la santé et des sports Valeurs biologiques usuelles, 2009. ,
Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C, 2014. ,
Critères diagnostiques et bilan initial de la cirrhose non compliquée, 2008. ,
Stages of hepatic fibrosis in chronic hepatitis according to the five stages (0-4) of the METAVIR scoring system, 1994. ,
Les manifestations extra-hépatiques au cours de l'infection par le virus de l'hépatite C, 2007. ,
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study, Hepatology, vol.34, issue.6, pp.1193-1202, 2001. ,
DOI : 10.1053/jhep.2001.29201
Chapitre 7 -Aspects postthérapeutiques des carcinomes hépatocellulaires, Imagerie Post-Thérapeutique en Oncologie [Internet], p.2014, 2015. ,
Variabilité génétique du virus de l'hépatite C : implications cliniques, p.98403, 2008. ,
Hépatite chronique C : Les stratégies thérapeutiques actuelles, J SIDA, issue.199, pp.13-19, 2007. ,
Historique du Virus de l'hépatite C et sa prise en charge, 2009. ,
Résumé des caractéristiques du produit du peginterféron alpha-2a (PEGASYS®), p.2013, 2015. ,
Guide de thérapeutique 2015 ,
Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int, pp.57-67, 2009. ,
Hépatite C : arrêt de la commercialisation du télaprévir le 30 avril, 2015. ,
Available from: https, 2015. ,
Résumé des caractéristiques du produit du siméprévir (OLYSIO®), p.2014, 2015. ,
Etude structurale et fonctionnelle de NS5B, l'ARN-polymérase du virus de l'hépatite C, par spectroscopie de résonance magnétique nucléaire, anx_129304_fr.pdf 52. European Medicines Agency, pp.2014-2014, 2014. ,
Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?, Antiviral Research, vol.107, pp.119-143, 2014. ,
DOI : 10.1016/j.antiviral.2014.04.008
Avis de la commission de transparence, 2014. ,
Monographie de INCIVO®, 2015. ,
INCIVO (télaprévir) : arrêt de commercialisation prévu le, 2015. ,
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013. ,
DOI : 10.1056/NEJMoa1214853
Masse molaire du sofosbuvir, 2014. ,
Sofosbuvir: A New Oral Once-Daily Agent for The Treatment of Hepatitis C Virus Infection, Pharm Ther, vol.39, issue.5, pp.345-52, 2014. ,
Sovaldi 400 mg cp pellic, 2014. ,
Résumé des caractéristiques du produit du sofosbuvir (SOVALDI®), p.2014, 2014. ,
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977, Journal of Biological Chemistry, vol.285, issue.45, pp.34337-34384, 2010. ,
DOI : 10.1074/jbc.M110.161802
-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus, Journal of Medicinal Chemistry, vol.53, issue.19, pp.7202-7220, 2010. ,
DOI : 10.1021/jm100863x
URL : https://hal.archives-ouvertes.fr/hal-00732567
Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase, Bioorganic & Medicinal Chemistry Letters, vol.13, issue.19, pp.3341-3345, 2003. ,
DOI : 10.1016/S0960-894X(03)00670-X
Résistance aux traitements [Internet]. 2015 Available from ,
Biology A2 revision OCR [Internet], 2014. ,
PSI-7851, a Pronucleotide of ??-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication, Antimicrobial Agents and Chemotherapy, vol.54, issue.8, pp.3187-96, 2010. ,
DOI : 10.1128/AAC.00399-10
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-na??ve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial, Journal of Hepatology, vol.58, issue.4, pp.663-671, 2013. ,
DOI : 10.1016/j.jhep.2012.11.018
Fixation des prix des médicaments, 2013. ,
Avis de la CT du 14 mai 2014, 2014. ,
Minimum costs to produce Hepatitis C Direct Acting Antivirals, 2015. ,
hépatite C peut coûter 705 euros en Inde et 41.000 euros en France [Internet] Available from: http://www.huffingtonpost.frsovaldi-prix-cout-france-hepatite-c_n_6190642.html 88. Food and Drug Administration. Sofosbuvir's cost, 2013. ,
Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies, Digestive and Liver Disease, vol.46, issue.5, pp.179-85, 2014. ,
DOI : 10.1016/j.dld.2014.09.026
Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC [Internet], 2013. ,
All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV ,
Sofosbuvir For Treatment of Chronic Hepatitis C Infection Available from: http://www.fda.gov, 2013. ,
Avis de la commission de transparence Available from, 2010. ,
Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study, EASL 48th Annual Meeting, 2013. ,
Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis, Human Immunology, vol.75, issue.12, pp.1268-75, 2014. ,
DOI : 10.1016/j.humimm.2014.09.005
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013. ,
DOI : 10.1056/NEJMoa1214853
Sofosbuvir Selects the NS5B S282T Mutation In Vitro in Genotype 1-6 Replicons and Is Not Cross-Resistant to Resistance-Associated Variants Selected by Other Classes of Antiviral Inhibitors. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC, 2013. ,
SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and noncirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC, 2013. ,
Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) Int Liver Congr 2014 49th Annu Meet Eur Assoc Study Liver Lond, 2014. ,
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, New England Journal of Medicine, vol.370, issue.3, pp.211-232, 2014. ,
DOI : 10.1056/NEJMoa1306218
All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial, p.2013, 2014. ,
Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) In Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) Or Boceprevir (BOC) Poster Abstr Sess Clin Trials IDWeek 2013 San Franc [Internet]. 2013; Available from: https, 2013. ,
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, 2014. ,
DOI : 10.1016/j.jhep.2014.10.044
Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC [Internet], 2013. ,
Diagnostics et thérapeutique de poche: Guide pratique du symptôme à la prescription, Armando Editore, 2009. ,
Prise en charge médicale des personnes vivant avec le VIH, actualisations 2014 du rapport 2013 ,
Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment, Journal of Gastroenterology and Hepatology, vol.46, issue.4, pp.512-532, 2008. ,
DOI : 10.1097/01.meg.0000224479.97169.e8
Mixed cryoglobulinemia, Orphanet Journal of Rare Diseases, vol.3, issue.1, p.25, 2008. ,
DOI : 10.1186/1750-1172-3-25
??valuation de l???efficacit?? virologique et de la tol??rance du traitement antiviral chez les patients porteurs d???une h??patite C chronique, associ??e ?? un lymphome B non hodgkinien??: ??tude cas-t??moins ANRS HC13??lympho-C, La Revue de M??decine Interne, vol.35, issue.2, pp.127-135, 2014. ,
DOI : 10.1016/j.revmed.2014.10.214
Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection, Alimentary Pharmacology and Therapeutics, vol.93, issue.3, pp.653-62, 2005. ,
DOI : 10.1046/j.1365-2141.1996.6912313.x
Prise en charge de l'hépatite C par les médicaments anti-viraux à action directe (AAD) 2014 [cited 2015 Feb 13]; Available from ,
Hepatitis C : New Drugs. hcvets *Internet+, 2012. ,
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential, Therapeutic Advances in Gastroenterology, vol.58, issue.567, pp.131-171, 2014. ,
DOI : 10.1056/NEJMoa1010494
The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications, Digestive and Liver Disease, vol.46, issue.5, pp.174-182, 2014. ,
DOI : 10.1016/j.dld.2014.09.028
Sofosbuvir as backbone of interferon free treatments, Digestive and Liver Disease, vol.46, issue.5, pp.212-232, 2014. ,
DOI : 10.1016/j.dld.2014.09.024
Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.3359-68, 2012. ,
DOI : 10.1128/AAC.00054-12
Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre, 2000. ,
Adverse Reactions from Clinical Trials Experience, 2014. ,
Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, vol.139, issue.5, pp.1602-1613, 1611. ,
DOI : 10.1053/j.gastro.2010.07.059
La physiologie de l'anémie isovolémique aiguë : Questions pratiques Anesth Conférences Sci [Internet] Available from, 2004. ,
Avis de la commission de transparence Available from: http://www.hassante.fr/portail/upload/docs/application, p.31440, 2011. ,
Interactions médicamenteuses liées à une inhibition de la P-glycoprotéine, 2004. ,
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C, Drugs, vol.58, issue.4 Suppl, pp.1127-1173, 2014. ,
DOI : 10.1007/s40265-014-0247-z
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs, Digestive and Liver Disease, vol.46, issue.5, pp.206-217, 2014. ,
DOI : 10.1016/j.dld.2014.09.027
Drug Safety and Availability -FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug, p.2015, 2015. ,
Antiviraux d'action directe contre l'hépatite C : éviter la prescription conjointe d'amiodarone, 2015. ,